Gelesis SRL appears in FDA device records as a legal applicant rather than as a brand or parent entity. Its single linked 510(k) record in the supplied collection is K261783, received May 29, 2026, with a substantially equivalent decision on October 2, 2026, a Traditional clearance type and a Summary statement. The applicant address in the filing is Via Europa 187, Calimera, Italy. The device is classified as an ingested, transient, space-occupying device for weight management and/or weight loss, assigned to the Gastroenterology, Urology advisory committee. [1][2][5]

The K261783 filing and its scope

K261783 covers Plenity-V (MC0979 / GS110) under regulation number 21 CFR 876.5982 and product code QFQ, with regulatory class II. The FDA decision letter is dated October 2, 2026 and lists the applicant as Gelesis SRL, addressed to Giorgio Sorcini as Sr. Dir. Design and RA. The letter records the submission as dated July 3, 2026 and received July 6, 2026, and the decision code is SESE, described as Substantially Equivalent. [1][2]

The FDA 510(k) final decisions listing for decisions rendered since October 1, 2026 includes K261783 with a Substantially Equivalent decision published October 2, 2026, naming Plenity-V (MC0979 / GS110) and Gelesis SRL as applicant. That listing places the clearance alongside unrelated October 2, 2026 decisions from other applicants. [5]

What changed in the device

The decision letter states that the device characteristics, specifications, design and performance are unchanged apart from replacement of the white porcine gelatin capsule with transparent HPMC components. That statement defines the documented difference between the subject device and its compared predicate as described in the letter. [2]

Applicant identity versus brand and predicate records

A separate 510(k), K230133, names Gelesis, Inc. of Boston, Massachusetts as applicant for a device called Plenity, with Giorgio Sorcini as correspondent contact and a decision date of January 19, 2024. The K230133 decision letter is addressed to Gelesis Inc. and identifies Giorgio Sorcini as Sr. Regulatory Affairs Director. These records establish a distinct legal applicant for that earlier filing; they do not establish that Gelesis SRL is the same legal entity, a subsidiary or a parent. [7][9]

Gelesis SRL's own website describes the company as developing GI and metabolic biomimetic therapies and refers to a proprietary superabsorbent hydrogel platform, with Plenity listed among its products. Those are company-published descriptions of technology and product positioning, not FDA findings. The site lists an address at Via Europa 187, Calimera, consistent with the filing address, but a filing address is not treated here as a verified headquarters designation. [4][6][8]

Collection context

The supplied portfolio snapshot, retrieved November 20, 2026, links one record to Gelesis SRL, a 510(k) with decision SESE; the decision counts show one SESE and the record sample contains only K261783. These figures describe the supplied collection at that timestamp and are not a measure of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]